MedPath

STRAGEN-FRANCE

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:11
Completed:2

Trial Phases

1 Phases

Phase 1:7

Drug Approvals

10

CIMA_AEMPS:9
SFDA:1

Drug Approvals

ABIRATERONA STRAGEN 250 MG COMPRIMIDOS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 10 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 25 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 20 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 15 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 5 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 2,5 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

LENALIDOMIDA STRAGEN 7,5 MG CAPSULAS DURAS EFG

Approval Date
Jul 14, 2025
CIMA_AEMPS

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (100.0%)

First-In-Human PainCart Study for STR-324

Phase 1
Completed
Conditions
Pain
Interventions
Drug: Placebo
Drug: STR-324 Dose Level A
Drug: STR-324 Dose Level B
Drug: STR-324 Dose Level C
Drug: STR-324 Dose Level 1
Drug: STR-324 Dose Level 2
Drug: STR-324 Dose Level 3
Drug: STR-324 Dose Level 4
Drug: STR-324 Dose Level 5
Drug: STR-324 Dose Level 6
Drug: STR-324 Dose Level 7
Drug: STR-324 Dose Level 8
First Posted Date
2018-02-12
Last Posted Date
2018-12-12
Lead Sponsor
Stragen France
Target Recruit Count
78
Registration Number
NCT03430232
Locations
🇳🇱

CHDR, Leiden, Netherlands

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.